Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [1] Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes
    Suganuma, Yumi
    Shimizu, Tatsunori
    Sato, Takehiro
    Morii, Tsukasa
    Fujita, Hiroki
    Sassa, Mariko Harada
    Yamada, Yuichiro
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (02) : 389 - 399
  • [2] Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
    Watchorn, David
    O'Shea, Donal
    Butler, Marcus W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (07) : 923 - 924
  • [3] Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Courtney, Hamish
    Nayar, Rahul
    Rajeswaran, Chinnadorai
    Jandhyala, Ravi
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 79 - 87
  • [4] Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella, Raffaella
    Pechtner, Valeria
    Corcos, Antonella
    Consoli, Agostino
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [5] Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 407 - 414
  • [6] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37
  • [7] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04) : 178 - 187
  • [8] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [9] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [10] Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study
    Takeshita, Yumie
    Kita, Yuki
    Tanaka, Takeo
    Goto, Hisanori
    Nakano, Yujiro
    Teramura, Chisato
    Enyama, Yasufumi
    Takamura, Toshinari
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (06) : 965 - 974